| Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice M Deodhar, SB Al Rihani, MJ Arwood, L Darakjian, P Dow, J Turgeon, ... Pharmaceutics 12 (9), 846, 2020 | 120 | 2020 |
| Respiratory dysfunction progresses with age in Kcna1‐null mice, a model of sudden unexpected death in epilepsy KA Simeone, J Hallgren, CS Bockman, A Aggarwal, V Kansal, L Netzel, ... Epilepsia 59 (2), 345-357, 2018 | 52 | 2018 |
| Risk assessment of drug‐induced long QT syndrome for some COVID‐19 repurposed drugs V Michaud, P Dow, SB Al Rihani, M Deodhar, M Arwood, B Cicali, ... Clinical and Translational Science 14 (1), 20-28, 2021 | 49 | 2021 |
| Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models S Al Rihani, M Deodhar, LI Darakjian, P Dow, MK Smith, R Bikmetov, ... Drugs & Aging, 2021 | 39 | 2021 |
| Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity D Lucy, M Deodhar, J Turgeon, V Michaud International Journal of Molecular Sciences 22 (9), 2021 | 38 | 2021 |
| Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition M Deodhar, SB Al Rihani, D Lucy, J Turgeon, V Michaud Pharmaceutics 13 (2:148), 2021 | 38 | 2021 |
| ACE2 as a therapeutic target for COVID-19; its role in infectious processes and regulation by modulators of the RAAS system V Michaud, M Deodhar, M Arwood, SB Al Rihani, P Dow, J Turgeon Journal of Clinical Medicine 9 (7), 2096, 2020 | 36 | 2020 |
| Disease-Induced Modulation of Drug Transporters at the Blood-Brain Barrier Level S Al Rihani, LI Darakjian, M Deodhar, P Dow, J Turgeon, V Michaud International Journal of Molecular Sciences 22 (7), 2021 | 28 | 2021 |
| Ketogenic diet regulates the antioxidant catalase via the transcription factor PPARγ2 S Knowles, S Budney, M Deodhar, SA Matthews, KA Simeone, ... Epilepsy research 147, 71-74, 2018 | 24 | 2018 |
| Risk of adverse drug events following the virtual addition of COVID-19 repurposed drugs to drug regimens of frail older adults with polypharmacy SB Al Rihani, MK Smith, R Bikmetov, M Deodhar, P Dow, J Turgeon, ... Journal of clinical medicine 9 (8), 2591, 2020 | 22 | 2020 |
| Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism M Deodhar, J Turgeon, V Michaud Pharmaceutics 13 (9), 2021 | 20 | 2021 |
| Is Dexamethasone a Substrate, an Inducer, or a Substrate-Inducer of CYP3As? S Al Rihani, M Deodhar, P Dow, J Turgeon, V Michaud Archives of Pharmacy and Pharmacology Research 2 (5), 2020 | 15 | 2020 |
| Pharmacoresponsiveness of spontaneous recurrent seizures and the comorbid sleep disorder of epileptic Kcna1-null mice M Deodhar, SA Matthews, B Thomas, L Adamian, S Mattes, T Wells, ... European journal of pharmacology 913, 174656, 2021 | 11 | 2021 |
| Risk of drug-induced Long QT Syndrome associated with the use of repurposed COVID-19 drugs: A systematic review V Michaud, P Dow, SBA Rihani, M Deodhar, M Arwood, B Cicali, ... MedRxiv, 2020.04. 21.20066761, 2020 | 11 | 2020 |
| An Illustrative Case of Phenoconversion due to Multi-Drug Interactions MV Deodhar Malavika, Dow Pamela, Al Rihani Sweilem B, Turgeon Jacques Clinical Case Reports Journal 1 (3), 1-6, 2020 | 8 | 2020 |
| Adverse drug event risk assessment by the virtual addition of COVID‐19 repurposed drugs to Medicare and commercially insured patients’ drug regimens: A drug safety simulation study MK Smith, R Bikmetov, SB Al Rihani, M Deodhar, M Hafermann, P Dow, ... Clinical and Translational Science 14 (5), 1799-1809, 2021 | 6 | 2021 |
| Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice. Pharmaceutics, 2020, 12 (9), 846 M Deodhar, SB Al Rihani, MJ Arwood, L Darakjian, P Dow, J Turgeon, ... | 6 | |
| Use of Drug Claims Data and a Medication Risk Score to Assess the Impact of CYP2D6 Drug Interactions among Opioid Users on Healthcare Costs V Michaud, R Bikmetov, MK Smith, P Dow, LI Darakjian, M Deodhar, ... Journal of Personalized Medicine, 2021 | 5 | 2021 |
| Assessing the mechanism of fluoxetine-mediated CYP2D6 inhibition. Pharmaceutics 2021; 13: 148 M Deodhar, SBA Rihani, L Darakjian, J Turgeon, V Michaud s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | 2 | 2021 |
| Development and Characterization of Pre-clinical Epilepsy Models to Evaluate Potential Anti-seizure Targets M Deodhar Creighton University, 2019 | 1 | 2019 |
Jacques TurgeonMontrealVerified email at umontreal.ca
